Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2010
06/16/2010CN101314046B Cyclodextrin inclusion method for hair orchid native
06/16/2010CN101284835B Dimeric sesquiterpene lactone compounds, preparation method and applications thereof
06/16/2010CN101284833B Compound bi-inulicin 4, preparation method and applications thereof
06/16/2010CN101250189B Bisfatty amido substituted quinazolone derivatives as well as preparation method and use thereof as anti-cancer drugs
06/16/2010CN101249071B Preparation of 2-methoxyl group estradiol vena nano emulsions
06/16/2010CN101225092B Manganese complex as well as preparation method and uses thereof
06/16/2010CN101200460B Dihydrobenzopyrans ketone compound and uses thereof
06/16/2010CN101175732B Production method for quinazoline derivatives and its application for producing medicine used for treating tumor disease
06/16/2010CN101156882B Preparation method of pseudo-ginseng protopanoxadiol saponin
06/16/2010CN101121019B Use of division deficient protein 3
06/16/2010CN101095822B Chinese traditional medicine composition for treating leukemia and method of making the same
06/16/2010CN101085308B Oral administration traditional Chinese medicine decoction for treating mammary cancer
06/16/2010CN101085269B Internal-applied traditional Chinese medicine composition for treating lung cancer
06/16/2010CN101045161B Modulators of P-selectin glycoprotein ligand 1
06/15/2010US7737285 [3-(4-{2-butyl-1-[4-(4chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine, used as modulators of the interaction between the receptor for advanced glycated end products and its ligands; inflammation, nephropathy, atherosclerosis, retinopathy, Alzheimer's disease, erectile dysfunction
06/15/2010US7737284 chemical condensation process to produce a chemical intermediates for antitumor agents; industrial scale, and provide good yields; simplification; efficiency
06/15/2010US7737264 Oligomeric compounds for the modulation HIF-1α expression
06/15/2010US7737255 monoclonal antibodies used for analyzing changes in the levels of cancer specific genes in cells, tissues or bodily fluids; medical prognosis
06/15/2010US7737144 1-Ethyl-6-methyl-3-phenyl-1H-pyrinido[5,4-e]1,2,4]triazine-5,7-dione, used for lowering blood sugar, treating non-insulin dependent diabetes and insulin resistance; antidiabetic agents
06/15/2010US7737136 high affinity agonists; high specificity; side effect reduction; endometriosis; hormone dependent cancers, fertility control; dibenzo[b,f]pyrido[1,2-d][1,4] oxazepin, dibenzo[b,f]pyrido[1,2-d][1,4]thiazepim, dibenzo[b,f]pyrido[1,2-d][1,4]diazepin and dibenzo[c,f]pyrido[1,2-a]azepine derivatives
06/15/2010US7737111 Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases
06/15/2010US7736899 Cells and method for producing proteins comprising an unconventional amino acid
06/15/2010US7736856 determining whether catechin or an antibody has the same pharmacological effect as that of epigallocatechin gallate, on inhibiting cell proliferation, angiogenesis or cancer cell metastasis, as a neuroprotectant, a viricide, an antiallergen and as a antiarteriosclerotic agent
06/15/2010US7736679 comprises curcumin and an essential oil of turmeric
06/15/2010US7736655 Neuroprotectants; angoigenesis inhibitors; transcription factors; host cells
06/15/2010US7736654 Proteins, polynucleotides, antibodies, transgenic animals, hybridoma; humoral or cellular immune response; pancreatic
06/15/2010US7736652 Comprises immunoglobulin-immunostimulant fusion protein for use in preventing and treating infections, cancer and autoimmune disorders; genetic vaccination; gene therapy
06/15/2010US7736640 administering to mammal more than one dose of a composition comprising live Newcastle Disease Virus in an amount sufficient to cause tumor regression
06/15/2010CA2518224C Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof
06/15/2010CA2495577C Novel benzoimidazole derivatives useful as antiproliferative agents
06/15/2010CA2493391C Novel thiophene glycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
06/15/2010CA2442256C Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
06/15/2010CA2440648C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
06/15/2010CA2419875C 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
06/15/2010CA2405050C Production of tcr gamma delta t cells
06/15/2010CA2404388C New prostate cell lines
06/15/2010CA2403168C Condensation derivatives of thiocolchicine and baccatin as antitumor agents
06/15/2010CA2393650C Novel 1,8-naphthyridin-2(1h)-one derivatives
06/15/2010CA2335505C Novel triterpenoids and their use for the treatment and prevention of cancer, inflammatory disorders, and neurodegenerative disease
06/15/2010CA2320288C Oligodeoxyribonucleotides comprising o6-benzylguanine and their use
06/15/2010CA2250080C Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
06/10/2010WO2010065962A2 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
06/10/2010WO2010065959A1 Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
06/10/2010WO2010065893A1 Raf inhibitors and their uses
06/10/2010WO2010065865A2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
06/10/2010WO2010065834A1 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
06/10/2010WO2010065825A2 Kinase inhibitors with improved cyp safety profile
06/10/2010WO2010065824A2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
06/10/2010WO2010065787A2 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
06/10/2010WO2010065685A1 Method of treating c-kit positive relapsed acute myeloid leukemia
06/10/2010WO2010065613A2 Annexina2 as immunological target
06/10/2010WO2010065563A2 Apratoxin therapeutic agents: mechanism and methods of treatment
06/10/2010WO2010065512A2 Compounds for treating proliferative disorders
06/10/2010WO2010065342A1 Angiocidin inhibition of tumor cell growth
06/10/2010WO2010065329A2 Nanoparticles for cancer treatment
06/10/2010WO2010065159A1 Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents
06/10/2010WO2010065134A1 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
06/10/2010WO2010065116A2 The use of il-27-p28 to antagonize il-6 mediated signaling
06/10/2010WO2010065079A2 Antibodies to il-6 and use thereof
06/10/2010WO2010065077A2 Antagonists of il-6 to prevent or treat thrombosis
06/10/2010WO2010064851A2 Mtor-targeted sirna having an interspecific cross reaction, recombination vector containing same, and pharmaceutical composition containing same
06/10/2010WO2010064838A2 Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient
06/10/2010WO2010064745A1 Acylamides inducing apoptosis of cancer cells
06/10/2010WO2010064737A1 Heterocyclic compound and use of the same
06/10/2010WO2010064736A1 Therapeutic agent for cancer
06/10/2010WO2010064722A1 Benzothiazole derivatives as anticancer agents
06/10/2010WO2010064707A1 2h-chromene compound and derivative thereof
06/10/2010WO2010064611A1 Heterocyclic compound and use thereof
06/10/2010WO2010064597A1 Piperidine derivative
06/10/2010WO2010064430A1 Wdrpuh epitope peptides and vaccines containing the same
06/10/2010WO2010064425A1 Method for inhibiting proliferation of cells
06/10/2010WO2010064422A1 Method for killing tumor by photosensitization treatment under conditions where histone is highly acetylated
06/10/2010WO2010064373A1 Il-8 inhibitor and process for producing same
06/10/2010WO2010064300A1 Composition for treatment of esophageal cancer
06/10/2010WO2010064111A1 Tnik inhibitor and the use
06/10/2010WO2010064090A1 Process for the modulation of the antagonistic activity of a monoclonal antibody
06/10/2010WO2010064089A1 Novel anti-cmet antibody
06/10/2010WO2010063802A1 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
06/10/2010WO2010063746A1 Process for the modulation of the antagonistic activity of a monoclonal antibody
06/10/2010WO2010063698A1 Treatment of oncological diseases
06/10/2010WO2010063696A1 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
06/10/2010WO2010063638A1 Bis [o-(14-benzoylaconine-8-yl)] esters
06/10/2010WO2010063472A1 Methods for preventing or reducing colon carcinogenesis
06/10/2010WO2010063470A2 Methods for preventing or reducing carcinogenesis or oxidative stress
06/10/2010WO2010063138A1 A monoclonal antibody specifically binding to vegf and the hybridoma secreting same and uses thereof
06/10/2010WO2010063069A1 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
06/10/2010WO2010045601A3 Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents
06/10/2010WO2010036404A3 Novel retinamide retinoic acid metabolism blocking agents
06/10/2010WO2010032093A3 Cytostatic composition
06/10/2010WO2010027513A3 Methods for killing psma-expressing, taxane-resistant cancer cells
06/10/2010WO2010022143A3 Assessing and treating breast cancer patients
06/10/2010WO2010021934A3 Azaindole inhibitors of iap
06/10/2010WO2010019954A3 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs
06/10/2010WO2010011349A3 Pyrimidine-2,4-diamines as jak2 kinase inhibitors for treatment of inflammation
06/10/2010WO2010011319A3 Magnetic heating for drug delivery and other applications
06/10/2010WO2009156041A3 Thiazolyl piperdine derivatives
06/10/2010WO2009147170A3 Drug combinations comprising a dgat inhibitor and a ppar-agonist
06/10/2010WO2009065561A8 System for delivery into a xcr1 positive cell and uses thereof
06/10/2010WO2009058267A3 Benzomorpholine derivatives and methods of use
06/10/2010US20100146650 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
1 ... 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 ... 2211